PCSK9 and endothelial dysfunction: However, despite the existence of molecular mechanisms indicating the direct participation of PCSK9 in endothelial dysfunction and arterial inflammation, a large set of previous clinical trials have found no change in systemic inflammatory markers after PCSK9i therapy [35, 36].